Celerion, a Lincoln, Nebraska-headquartered company that provides early clinical research and translational clinical pharmacology sciences, has appointed Dr. Marc Hoffman as chief medical officer (CMO).
Dr. Hoffman joins Celerion from Patient identification Platform (Patient iP), a Rochester, New York-based company that provides site selection and clinical-trial matching technology, where he served as CMO. Prior to joining Patient iP, he held the roles of CMO and senior vice president and general manager over the biopharmaceutical business at Theorem Clinical Research, a contract research organization based in King of Prussia, Pennsylvania. Previously in his career, Dr. Hoffman held senior-level positions in medical and scientific affairs at Baxter, Hospira, and Covance.
Dr. Hoffman brings over 28 years of knowledge and experience as a physician in the pharmaceutical, device, and CRO industries. He is experienced in global drug development, medical affairs, pharmacovigilance and regulatory affairs, and has a track record in building, managing, and globalizing medical teams.